BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27112922)

  • 41. Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia.
    Zhou WL; Wu HB; Wang LJ; Tian Y; Dong Y; Wang QS
    Eur J Radiol; 2016 Jan; 85(1):205-210. PubMed ID: 26724667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual-phase F-18 FDG PET-CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers.
    Sürücü E; Polack BD; Demir Y; Durmuşoğlu M; Ekmekçi S; Sarıoğlu S; Çelik AO; Ada E; İkiz AÖ
    Clin Imaging; 2015; 39(5):781-6. PubMed ID: 25721710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PET/CT findings in acute gastric anisakiasis.
    Abe K; Yoshikai T; Baba S; Isoda T; Honda H
    Clin Nucl Med; 2014 Jun; 39(6):e340-2. PubMed ID: 24810783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
    Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
    J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging.
    Panagiotidis E; Datseris IE; Exarhos D; Skilakaki M; Skoura E; Bamias A
    Nucl Med Commun; 2012 Apr; 33(4):431-8. PubMed ID: 22293498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-FDG PET in the management of endometrial cancer.
    Chao A; Chang TC; Ng KK; Hsueh S; Huang HJ; Chou HH; Tsai CS; Yen TC; Wu TI; Lai CH
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):36-44. PubMed ID: 16167154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.
    Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA
    Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Splenic and multiple abdominal metastases of endometrial carcinoma detected with FDG-PET/CT.
    Kara T; Kara PO; Gedik GK; Sari O
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):31-3. PubMed ID: 21737185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology.
    El-Bawab H; Al-Sugair AA; Rafay M; Hajjar W; Mahdy M; Al-Kattan K
    Eur J Cardiothorac Surg; 2007 Apr; 31(4):731-6. PubMed ID: 17293120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
    Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
    Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sarcoidosis mimicking metastatic gynaecological malignancies: a diagnostic and therapeutic challenge?
    Mapelli P; Mangili G; Picchio M; Rabaiotti E; Gianolli L; Messa C; Candiani M
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):314-7. PubMed ID: 23270913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy of preoperative positron emission tomography-computed tomography (PET-CT) for detection of lymph node metastasis in cervical and endometrial cancer: clinical and pathological factors influencing it.
    Nogami Y; Banno K; Irie H; Iida M; Kisu I; Masugi Y; Tanaka K; Tominaga E; Okuda S; Murakami K; Aoki D
    Jpn J Clin Oncol; 2015 Jan; 45(1):26-34. PubMed ID: 25368102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy.
    Lee JE; Hong SP; Ahn DH; Jeon TJ; Kang MK; Kwon CI; Ko KH; Hwang SG; Park PW; Rim KS
    Yonsei Med J; 2011 Jan; 52(1):81-8. PubMed ID: 21155039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT.
    Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Morita S; Suganuma N; Sugimura K
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):362-72. PubMed ID: 18931841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. JAZF1-SUZ12 endometrial stromal sarcoma forming subserosal masses with extraordinary uptake of fluorodeoxyglucose on positron emission tomography: a case report.
    Fujiishi K; Nagata S; Kano R; Kubo C; Shirayanagi M; Ozaki M; Yamamoto T; Nakanishi K; Kamiura S; Nakatsuka SI
    Diagn Pathol; 2019 Oct; 14(1):110. PubMed ID: 31615558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.